PE20110023A1 - Composiciones inmunogenicas de antigenos de staphylococcus aureus - Google Patents

Composiciones inmunogenicas de antigenos de staphylococcus aureus

Info

Publication number
PE20110023A1
PE20110023A1 PE2010000420A PE2010000420A PE20110023A1 PE 20110023 A1 PE20110023 A1 PE 20110023A1 PE 2010000420 A PE2010000420 A PE 2010000420A PE 2010000420 A PE2010000420 A PE 2010000420A PE 20110023 A1 PE20110023 A1 PE 20110023A1
Authority
PE
Peru
Prior art keywords
aureus
isolated
polypeptide
staphylococcus aureus
clfb
Prior art date
Application number
PE2010000420A
Other languages
English (en)
Inventor
Annaliesa Anderson
Viliam Pavliak
Kathrin Ute Jansen
Ingrid Lea Dodge
Steven Morris Baker
Jasdeep Singh Nanra
Ellen Murphy
Bruce Arthur Green
Mark Edward Ruppen
Yekaterina Timofeyeva
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PE20110023A1 publication Critical patent/PE20110023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE REFIERE A UNA COMPOSICION INMUNOGENICA QUE CONTIENE AL MENOS TRES COMPONENTES DE ENTRE: A) UN POLIPEPTIDO DEL FACTOR AGLUTINANTE A AISLADO DE S. AUREUS (ClfA); B) UN POLIPEPTIDO DEL FACTOR AGLUTINANTE B AISLADO DE S. AUREUS (ClfB), DONDE EL POLIPEPTIDO ClfA O ClfB ES UN FRAGMENTO DE POLIPEPTIDO QUE COMPRENDE LOS DOMINIOS N1, N2 Y N3 DE ENLACE A FIBRINOGENO, LOS CUALES SE ENLAZAN A TRAVES DE UNA SUSTITUCION DE AMINOACIDO DE ALA O SER EN TYR 338, TYR 256, PRO 336, LYS 389, ALA 254 E ILE 387; C) UN POLISACARIDO CAPSULAR DE S. AUREUS AISLADO TIPO 5 O-ACETILADO EN UN 10% A 100%, CONJUGADO A UNA PROTEINA PORTADORA QUE ES EL TOXOIDE CRM197 DE C. DIPHTHERIAE; D) UNA PROTEINA MntC AISLADA DE S. AUREUS QUE PUEDE ESTAR LIPIDADA O NO; E) UN POLISACARIDO CAPSULAR TIPO 8 AISLADO DE S. AUREUS O-ACETILADO EN UN 10% A 100%, CONJUGADO A UNA PROTEINA PORTADORA QUE ES EL TOXOIDE CRM197 DE C. DIPHTHERIAE. SE REFIERE TAMBIEN A UN METODO PARA INDUCIR UNA RESPUESTA INMUNE CONTRA STAPHYLOCOCCUS AUREUS QUE COMPRENDE LA GENERACION DE ANTICUERPOS QUE TIENEN ACTIVIDAD OPSONOFAGOCITICA (OPA) CONTRA S. AUREUS
PE2010000420A 2009-06-22 2010-06-22 Composiciones inmunogenicas de antigenos de staphylococcus aureus PE20110023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21913409P 2009-06-22 2009-06-22

Publications (1)

Publication Number Publication Date
PE20110023A1 true PE20110023A1 (es) 2011-01-31

Family

ID=42542752

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2010000420A PE20110023A1 (es) 2009-06-22 2010-06-22 Composiciones inmunogenicas de antigenos de staphylococcus aureus
PE2014001322A PE20142188A1 (es) 2009-06-22 2010-06-22 Composiciones inmunogenicas de antigenos de staphylococcus aureus

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014001322A PE20142188A1 (es) 2009-06-22 2010-06-22 Composiciones inmunogenicas de antigenos de staphylococcus aureus

Country Status (27)

Country Link
US (3) US8568735B2 (es)
EP (2) EP2445522B1 (es)
JP (3) JP5395264B2 (es)
KR (1) KR101486122B1 (es)
CN (2) CN102481352A (es)
AR (2) AR078601A1 (es)
AU (1) AU2010264538B2 (es)
BR (1) BRPI1015567A2 (es)
CA (1) CA2766629C (es)
CO (1) CO6480925A2 (es)
DK (1) DK2445522T3 (es)
ES (1) ES2642076T3 (es)
HU (1) HUE036372T2 (es)
IL (1) IL217084B (es)
MX (2) MX2012000044A (es)
MY (1) MY169837A (es)
NZ (1) NZ597154A (es)
PE (2) PE20110023A1 (es)
PL (1) PL2445522T3 (es)
PT (1) PT2445522T (es)
RU (1) RU2536981C9 (es)
SA (1) SA110310528B1 (es)
SG (3) SG10201406520YA (es)
SI (1) SI2445522T1 (es)
TW (1) TWI469789B (es)
WO (1) WO2010151544A1 (es)
ZA (1) ZA201200501B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
NZ553776A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
WO2011005341A2 (en) 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
JP5395264B2 (ja) 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物
TR201809128T4 (tr) 2009-07-15 2018-07-23 Aimm Therapeutics Bv Gram-pozitif bakterilere spesifik bağlanan bileşikler.
MX2012004851A (es) * 2009-10-30 2012-05-22 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
ES2769425T3 (es) * 2010-12-22 2020-06-25 Wyeth Llc Composiciones inmunogénicas estables de antígenos de Staphylococcus aureus
US9527905B2 (en) * 2011-02-08 2016-12-27 Medimmune, Llc Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use
CN105693865B (zh) * 2011-06-01 2020-07-17 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
EA035513B1 (ru) * 2011-07-22 2020-06-29 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" ВАКЦИНА, СОДЕРЖАЩАЯ БЕЛОК Als3, ДЛЯ ЛЕЧЕНИЯ У МЛЕКОПИТАЮЩЕГО АБСЦЕССА КОЖИ, ОБУСЛОВЛЕННОГО STAPHYLOCOCCUS AUREUS
BR112014004782A2 (pt) * 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
CA2928543A1 (en) 2012-10-26 2014-05-01 Gunnar F. Kaufmann Anti-infective binding proteins that bind aip2
KR102288394B1 (ko) * 2012-11-06 2021-08-09 메디뮨 엘엘씨 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
EA030005B1 (ru) 2013-03-15 2018-06-29 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
JP6560195B2 (ja) * 2013-05-21 2019-08-14 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 黄色ブドウ球菌のＬｕｋＧＨ（ＬｕｋＡＢ）毒素を中和する、非常に強力な抗体の生成
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN103412122B (zh) * 2013-08-09 2015-06-24 安徽农业大学 同步检测金葡菌a型和g型肠毒素的基于多表位串联肽的间接竞争elisa方法
CN103951749B (zh) * 2014-04-18 2017-07-11 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌eLtaS蛋白的单克隆中和性抗体E4‑2的制备及其应用
CN103951748B (zh) * 2014-04-18 2017-07-11 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌eLtaS蛋白的单克隆中和性抗体E4‑1的制备及其应用
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
US11097000B2 (en) * 2016-10-03 2021-08-24 National Taiwan University Klebsiella pneumoniae capsule polysaccharide vaccines
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN106544432A (zh) * 2016-11-08 2017-03-29 江苏大学 一种金黄色葡萄球菌耐药性和毒力快速检测方法及试剂盒
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same
US10774135B2 (en) 2017-12-22 2020-09-15 Sorrento Therapeutics, Inc. Variant antibodies that bind AIP2
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
RU2707922C1 (ru) * 2019-06-27 2019-12-02 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Рекомбинантная плазмидная ДНК pQE-30_P36GP12_GP57, обеспечивающая синтез рекомбинантного белка P36GP12 в клетках Escherichia coli, штамм бактерий Escherichia coli - продуцент рекомбинантного белка P36GP12, рекомбинантный белок P36GP12, обладающий способностью связывать липополисахариды Escherichia coli
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN111072775B (zh) * 2019-12-26 2021-08-20 成都欧林生物科技股份有限公司 抗MntC蛋白抗体及其应用和包含其的试剂盒
CN111138551A (zh) * 2020-01-15 2020-05-12 黑龙江八一农垦大学 一种预防金黄色葡萄球菌和白色念珠菌感染的atm融合蛋白的制备及应用
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024002331A1 (en) * 2022-06-30 2024-01-04 Shanghai Yuguan Biotech Co., Ltd. A live bacteria strain with reduced capsules
CN118146362A (zh) * 2024-03-15 2024-06-07 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌锰离子转运蛋白c的抗体及其应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134214A (en) 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
CA2047031A1 (en) 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5635348A (en) 1990-10-05 1997-06-03 Hoffmann-La Roche Inc. Method and probes for identifying bacteria found in blood
AU681573B2 (en) 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
US5980908A (en) 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE197506T1 (de) 1992-03-19 2000-11-11 Jackson H M Found Military Med Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
DE69434079T2 (de) 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
PT783520E (pt) 1994-09-21 2002-05-31 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
EP0857214A1 (en) 1995-10-16 1998-08-12 Smithkline Beecham Plc Novel saliva binding protein
US6593114B1 (en) 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
JP4235262B2 (ja) 1997-06-12 2009-03-11 シンエツ・バイオ，インコーポレイテッド 組換え細菌宿主における非生来細菌性エキソ多糖の産生
EP1000076A1 (en) 1997-07-17 2000-05-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES HEXADECASACCHARIDE-PROTEIN CONJUGATE VACCINE FOR $i(SHIGELLA DYSENTERIAE) TYPE 1
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
WO1999027109A2 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS)
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
IL141691A0 (en) 1998-08-31 2002-03-10 Trinity College Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
WO2000012131A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Multicomponent vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
AU5867100A (en) 1999-05-03 2000-12-12 Medarex, Inc. Human antibodies to staphylococcus aureus
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AU1478301A (en) 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
AU2001247697B2 (en) 2000-03-22 2006-06-22 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
SK287689B6 (sk) 2000-06-08 2011-06-06 Intercell Ag Použitie molekuly oligodeoxynukleovej kyseliny na výrobu imunostimulačnej farmaceutickej kompozície a farmaceutický prípravok
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2002256985B8 (en) 2001-01-26 2008-03-20 Inhibitex, Inc Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
WO2002098369A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ATE451386T1 (de) 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
JP4424984B2 (ja) 2001-06-15 2010-03-03 インヒビテックス インコーポレーテッド コアグラーゼ陰性ブドウ球菌および黄色ブドウ球菌由来の表面蛋白質を認識する、交差反応性モノクローナルおよびポリクローナル抗体
CA2351018A1 (en) 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
CA2808598A1 (en) 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
FR2828404B1 (fr) 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
JP2005536185A (ja) 2002-03-05 2005-12-02 インヒビテックス インコーポレーテッド コアグラーゼ陰性ブドウ球菌タンパク質を認識するモノクローナルおよびポリクローナル抗体
DE60325565D1 (de) 2002-03-26 2009-02-12 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
TW200306314A (en) 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
EP1565478B1 (en) 2002-11-12 2017-08-02 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
JP4078417B2 (ja) 2003-03-04 2008-04-23 独立行政法人産業技術総合研究所 好熱菌由来オリゴペプチダーゼ
CA2517439C (en) * 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP1608756B1 (en) 2003-03-31 2009-11-18 Intercell AG Staphylococcus epidermidis antigens
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
SG182163A1 (en) 2003-12-17 2012-07-30 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
US7537766B2 (en) 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
GB0421079D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Immunogenic composition
US8445000B2 (en) 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
PT1896065E (pt) 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Processo para a preparação de vacinas
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
EP1998802A2 (en) * 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
MY150927A (en) 2007-03-23 2014-03-14 Wyeth Corp Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
JP5709527B2 (ja) 2008-01-31 2015-04-30 ザ プロボスト フェローズ アンドスカラーズ オブ ザ カレッジ オブ ザ ホーリー アンド アンディバイデッドトリニティー オブ クイーン エリザベス ニア ダブリン 微生物感染症の治療
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
JP5395264B2 (ja) 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物
CA2768485C (en) 2009-07-16 2018-12-04 Timothy Foster Treatment of staphylococci infections using recombinant fibrinogen binding protein clumping factor a
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX2012004851A (es) 2009-10-30 2012-05-22 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
ES2769425T3 (es) 2010-12-22 2020-06-25 Wyeth Llc Composiciones inmunogénicas estables de antígenos de Staphylococcus aureus

Also Published As

Publication number Publication date
US20150132336A1 (en) 2015-05-14
JP6067806B2 (ja) 2017-01-25
US20140017271A1 (en) 2014-01-16
AR078601A1 (es) 2011-11-23
AR119682A2 (es) 2022-01-05
HUE036372T2 (hu) 2018-07-30
RU2011151781A (ru) 2013-07-27
CA2766629C (en) 2020-03-24
JP2012530786A (ja) 2012-12-06
AU2010264538A1 (en) 2012-01-19
RU2536981C9 (ru) 2015-05-10
SA110310528B1 (ar) 2014-07-02
IL217084B (en) 2018-11-29
KR20120046189A (ko) 2012-05-09
SG10201406520YA (en) 2014-11-27
IL217084A0 (en) 2012-02-29
SG176837A1 (en) 2012-01-30
KR101486122B1 (ko) 2015-01-23
AU2010264538B2 (en) 2013-10-03
PE20142188A1 (es) 2014-12-29
PL2445522T3 (pl) 2018-01-31
CO6480925A2 (es) 2012-07-16
ES2642076T3 (es) 2017-11-15
TW201103557A (en) 2011-02-01
JP2013151501A (ja) 2013-08-08
JP5395264B2 (ja) 2014-01-22
PT2445522T (pt) 2017-10-04
CA2766629A1 (en) 2010-12-29
TWI469789B (zh) 2015-01-21
RU2536981C2 (ru) 2014-12-27
BRPI1015567A2 (pt) 2021-08-31
DK2445522T3 (en) 2017-09-25
EP2445522B1 (en) 2017-08-09
SI2445522T1 (sl) 2017-10-30
US8568735B2 (en) 2013-10-29
MY169837A (en) 2019-05-16
CN102481352A (zh) 2012-05-30
JP2016034956A (ja) 2016-03-17
ZA201200501B (en) 2012-10-31
SG10201707084SA (en) 2017-10-30
US20120107327A1 (en) 2012-05-03
EP3238742A1 (en) 2017-11-01
CN107096020A (zh) 2017-08-29
MX2012000044A (es) 2012-01-30
MX343111B (es) 2016-10-25
WO2010151544A1 (en) 2010-12-29
EP2445522A1 (en) 2012-05-02
NZ597154A (en) 2013-10-25
JP5870052B2 (ja) 2016-02-24
US8889145B2 (en) 2014-11-18
US9114105B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
CY1121023T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CY1118221T1 (el) Εκλεκτικοι συνδετες συνδεσης οψινης, συνθεσεις και μεθοδοι χρησης
CR20150097A (es) Composición inmunogénica
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
NO20083793L (no) Antistoffer mot amyloid-beta peptid
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
BRPI0515316A (pt) compostos de imidazoquinolina
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
CO6382140A2 (es) Composiciones de vacuna que comprenden una proteina de enlace del factor h mutada
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
PE20070499A1 (es) Composicion inmunogenica
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
CL2009000757A1 (es) Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras.
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
EA200701911A1 (ru) Химерные рекомбинантные антигены toxoplasma gondii
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas

Legal Events

Date Code Title Description
FG Grant, registration